Clinical Trial Update: Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating sitravatinib with or without tislelizumab in unresectable or metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Sitravatinib (sitravatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Melanoma | Phase 2 | Status: UNKNOWN